Anticancer activity and other biomedical properties of β‐sitosterol: Bridging phytochemistry and current pharmacological evidence for future translational approaches

S Nandi, A Nag, S Khatua, S Sen… - Phytotherapy …, 2024 - Wiley Online Library
Sterols, including β‐sitosterol, are essential components of cellular membranes in both plant
and animal cells. Despite being a major phytosterol in various plant materials …

Pharmacological properties of mangiferin: Bioavailability, mechanisms of action and clinical perspectives

J Zivković, KA Kumar, R Rushendran, K Ilango… - Naunyn-Schmiedeberg's …, 2024 - Springer
This review aims to provide an in-depth analysis of the pharmacological properties of
mangiferin, focusing primarily on its bioavailability and mechanisms of action, and its …

A global action agenda for turning the tide on fatty liver disease

JV Lazarus, HE Mark, AM Allen, JP Arab, P Carrieri… - Hepatology, 2024 - journals.lww.com
Conclusions: This consensus-driven multidisciplinary fatty liver disease action agenda
developed by care providers, clinical researchers, and public health and policy experts …

Current status and future trends of the global burden of MASLD

L Miao, G Targher, CD Byrne, YY Cao… - Trends in Endocrinology & …, 2024 - cell.com
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most
common chronic liver disease globally, affecting more than a third of the world's adult …

[HTML][HTML] The burden of liver disease in Latin America

LA Díaz, M Villota-Rivas, F Barrera, JV Lazarus… - Annals of …, 2024 - Elsevier
Liver disease poses a substantial burden in Latin America. This burden is primarily
attributed to a high level of alcohol consumption and the increasing prevalence of risk …

[HTML][HTML] Portal vein thrombosis in patients with hepatocellular carcinoma and early cirrhosis—prevalence and risk factors

MTUH Siddiqui, G Fareed, MR Khan, A Riaz… - …, 2023 - ncbi.nlm.nih.gov
Method A retrospective analysis was performed on the prospectively collected data from
January 2018 to March 2020. All patients with HCC discussed in our weekly …

Nonalcoholic Fatty Liver Disease Gets Renamed as Metabolic Dysfunction–Associated Steatotic Liver Disease: Progress But With Challenges

AM Allen, E Pose, KR Reddy, MW Russo, PS Kamath - Gastroenterology, 2024 - Elsevier
Conclusions To summarize, while renaming and redefining the disease was needed, the
implementation is not without challenges (Table 1). A more complex classification may add …

[PDF][PDF] A global research priority agenda to advance public health responses to fatty liver

JV Lazarus, HE Mark, AM Allen, JP Arab, P Carrieri… - 2023 - discovery.dundee.ac.uk
Nonalcoholic fatty liver disease, hereafter referred to simply as fatty liver disease, is the most
widespread liver disease, with an estimated prevalence of 38% of the global adult …